Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
NCT ID: NCT00581425
Last Updated: 2013-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
49 participants
INTERVENTIONAL
2007-12-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aldara for the Treatment of Large and/or Multiple sBCC
NCT00189280
Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
NCT00079300
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas
NCT04570683
Clinical Study Protocol for Cutaneous SCC for Immunocompromised Patients
NCT06615635
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
NCT03958383
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treated
Imiquimod and Interferon alpha
Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imiquimod and Interferon alpha
Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Texas Health Science Center, Houston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephen Tucker
Visiting Professor - Dermatology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen B Tucker, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Texas Health Science Center of Houston Dermatology Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Health Science Center of Houston Dermatology Clinic
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OSP-24412
Identifier Type: -
Identifier Source: secondary_id
HSC-MS-06-0478
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.